title: Insurers will find icatibant lifesaving but expensive treatment. Managed care once again faces the all-too-familiar debate about cost and benefit.
authors.affiliation: National Association of Managed Care Physicians, USA. TMorrow@ManagedCareMag.com
authors.forename: Thomas
authors.initials: T
authors.lastname: Morrow
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000191:economics* / Q000627:therapeutic use; D054179:Angioedemas, Hereditary / Q000188:drug therapy / Q000503:physiopathology; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D008329:Managed Care Programs; D014481:United States
chemical_list: D000319:Adrenergic beta-Antagonists; C065679:icatibant; D001920:Bradykinin